2901 Phase 2 study of VB-, an anti-cancer gene therapy, as monotherapy followed by combination of VB-111 with bevacizumab, in patients with recurrent glioblastoma. (September 2015) - Brenner, A.; Cohen, Y.; Vredenburgh, J.; Peters, K.; Nayak, L.; Blumenthal, D.; Bokstein, F.; Breitbart, E.; Bangio, L.; Sher, N.; Harats, D.; Wen, P.